<DOC>
	<DOCNO>NCT00848939</DOCNO>
	<brief_summary>This study assess pharmacokinetic safety profile treprostinil follow fix escalate dos treprostinil diethanolamine SR tablet . Open-label , two-part study assess pharmacokinetics , safety , tolerability oral treprostinil diethanolamine SR. Cohort 1 : single 1 mg treprostinil diethanolamine SR dose . Cohort 2 : escalating dos treprostinil diethanolamine SR target dose 4 mg BID .</brief_summary>
	<brief_title>Pharmacokinetics Oral Treprostinil Patients With Systemic Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Scleroderma , Systemic</mesh_term>
	<mesh_term>Scleroderma , Diffuse</mesh_term>
	<mesh_term>Treprostinil</mesh_term>
	<criteria>Subject give voluntary write informed consent participate study . Subject diagnose systemic sclerosis ( SSc ) define American College Rheumatology ( ACR ) criterion . Males females age great 18 year time Screening . Presence active digital ulcer OR history digital ulcer occur within past 6 month time Screening poorly control Raynaud 's phenomenon ( documented patient report 610 episode per week ) . Females childbearing potential must willing use two form medically acceptable contraception ( least one barrier method ) negative pregnancy test Screening , confirm Baseline separate visit . Women surgically sterile postmenopausal least 2 year consider childbearing potential . Subject agree abstain consume grapefruit contain food beverage 3 day prior Baseline discharge study . Subject able communicate effectively study personnel consider reliable , willing cooperative term compliance protocol requirement . Has diagnosis pulmonary arterial hypertension receive approve investigational therapy PAH , include endothelin receptor antagonist , phosphodiesterase inhibitor , prostacyclin analogue . Body weight less 40 kg time Screening , confirm Baseline . The subject history postural hypotension , unexplained syncope , blood pressure le 85 mmHg systolic 50 mmHg diastolic Screening Baseline . Hemoglobin concentration le 75 % low limit normal range time Screening . AST and/or ALT concentration great 3 time upper limit normal ( ULN ) time Screening . Moderate severe hepatic impairment , i.e. , ChildPugh Class B C. Intractable diarrhea , severe malabsorption , define great 15 % unintentional loss body weight last 6 month prior Screening , severe organ failure ( e.g. , lung , kidney ) lifethreatening condition . Pregnancy breastfeed . Overlap another connective tissue disease could affect rest pain hand function ( e.g . diabetes mellitus , rheumatoid arthritis ) . Sympathectomy upper limb perform within 12 month Baseline . Receipt parenteral prostanoid treatment ( epoprostenol , treprostinil sodium , prostacyclin analog ) within previous 3 month condition include PAH , rest pain / digital ulcer . Treatment gemfibrozil , glitazones , cyclophosphamide within 1 week prior Baseline . Treatment rifampin within 4 week prior Baseline . Local injection botulinum toxin affect finger within 1 month prior Baseline . Received systemic antibiotic treat infection digital ulcer within 2 week prior Baseline . Treatment phosphodiesterase inhibitor sildenafil , except intermittent treatment male erectile dysfunction . Received investigational product within 1 month precede Screening . Known hypersensitivity oral treprostinil excipients . Cigarette smoke level within past 6 month prior Screening . Any condition could prevent compliance protocol adherence therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>systemic sclerosis</keyword>
	<keyword>scleroderma</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>treprostinil diethanolamine</keyword>
</DOC>